Health · Medical Research · 3 hrs ago
Malaria antibody protected infants but weakened vaccine response in study
Researchers tested the L9LS malaria antibody in infants in Mali and found it protected them against malaria over a six-month transmission season.
The antibody was 78% effective compared with a placebo, but it also reduced antibody levels from the R21 vaccine by 20% to 30%.
It is not yet clear whether that lower response in blood tests means the vaccine would provide less protection in everyday life.
Malaria vaccines require multiple doses, with the first given at five months of age, while one antibody shot may protect for several months.
Malaria killed about 610,000 people in 2024, most of them children under five in sub-Saharan Africa.
The results raise questions about giving L9LS and R21 to infants together, even though the antibody could offer another way to protect children during malaria season.
Researchers plan to focus pivotal studies on groups other than babies and hope to start those studies in 2028.
L9LS, a monoclonal antibody tested in infants in Mali, was 78% effective against malaria over a six-month transmission season.
The study also found that L9LS reduced antibody levels produced by the R21 malaria vaccine by 20% to 30%.
Researchers said it is unclear whether the weaker blood-test response would reduce the vaccine’s real-world protection.
They plan to focus upcoming pivotal studies on groups other than babies, with the studies hoped to start in 2028.
A single antibody injection could provide several months of protection, while malaria vaccines require multiple doses and begin at 5 months of age.
- Who
- Researchers tested the L9LS monoclonal antibody in infants in Mali.
- What
- L9LS protected infants against malaria but lowered antibody levels generated by the R21 vaccine.
- When
- The findings were detailed on Thursday and published on November 19, 2026.
- Where
- The study took place in Mali.
- Why
- Researchers are assessing L9LS as a way to protect against malaria; the study found that giving it before R21 affected the vaccine’s immune response.
This story does not have two clearly opposing sides.
L9LS provided 78% protection against the malaria parasite compared with a placebo.
Researchers detailed the findings at the annual meeting of the American Society of Tropical Medicine and Hygiene.
Researchers hope to start pivotal studies focused on groups other than babies.
- Study location
- Mali
- L9LS effectiveness
- 78% versus placebo over six months
- R21 antibody levels
- 20% to 30% lower after immunization
- Infant ages
- 1 month to 12 months
- Planned pivotal studies
- Researchers hope to start in 2028
1 source
What people are saying
We have these other clear use cases, so let’s get those done and get it approved and we can come back and revisit this
A monoclonal antibody, with only one shot, provides an efficacy over six months, and those six months correspond to the season of malaria in Sahelian regions.
In terms of logistics, in terms of programmatical use, this could be a very good tool.